Navigation Links
ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River
Date:7/27/2010

ion or how to vote their shares may contact the company's proxy solicitor, MacKenzie Partners Inc., toll-free, at (800) 322- 2885.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

    WuXi:
     Ronald Aldridge
     Director of Investor Relations, WuXi
     Phone: +1-201-585-2048
     Email: ir@wuxiapptec.com

    Sard Verbinnen & Company
     George Sard/Brandy Bergman/Jonathan Doorley
     Phone: +1-212-687-8080
     Email: jdoorley@sardverb.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
2. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
5. Task Force Recommends Screening for Hearing Loss in All Newborns
6. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
7. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
8. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
9. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
10. Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
11. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
(Date:7/24/2014)... Inc. (NYSE MKT: IG), a New Jersey based specialty generic ... the second quarter ended June 30, 2014. Second ... million in the second quarter of 2014, an increase of ... revenues of $13.3 million for the six months ended June ... in 2013 , Total revenues generated from the sale ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
(Date:7/27/2014)... 2014 This is a professional ... Dutasteride (CAS 164656-23-9) industry. The report firstly reviews ... its classification, application and manufacturing technology. The report ... Dutasteride (CAS 164656-23-9) listing their product specification, capacity, ... report further analyzes quantitatively 2009-2014 global and China’s ...
(Date:7/27/2014)... July 27, 2014 The report ... in Aviation - Market Analysis (Commercial Aviation And ... Pneumatic, Hydraulic, Mechanical) - Forecasts 2014 - 2019." ... are expected to shape the market during the ... and technology trends that are currently prevailing in ...
(Date:7/27/2014)... News) -- Couples aren,t more likely to get divorced ... new research finds. The study only looks at ... play a direct role in affecting whether couples stay ... speak against fears that women,s growing educational advantage over ... Schwartz, lead author of the study, said in an ...
(Date:7/27/2014)... July 27, 2014 Alta Resources ... outsourcing (BPO) for Fortune 500 brands, announced today that ... its locations in Wisconsin, California, Florida and the Philippines. ... several health-insurance clients, which have seasonal ramp-ups that require ... (AEP), November 2014 through February 2015. As more consumers ...
(Date:7/27/2014)... 27, 2014 The Institute of Safe ... adverse events such as Xarelto bleeding side-effects reported after ... out numbered the complaints filed for its competitor Pradaxa, ... for Xarelto increased to nearly 1 million prescriptions per ... early 2012, the ISMP noted in its latest issue ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 2Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 4Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 5
... chronic hepatitis C are at risk of suffering from ... weeks from commencement of treatment, says the researchers in a ... Science (IOVS)in the January 2007 issue. ,Researchers from ... in diameter of blood vessels and the velocity of ...
... that suggests a link between a particular gene named ... journal, Neurobiology of Aging, published the results of the ... implicated in causing Alzheimer’s disease. ,This research now ... raises the possibility that occurrence of herpes infection earlier ...
... have to prescribe medicines by their generic names instead of ... ,"We have issued a letter in this regard to all ... and dispensaries," Singh told IANS. ,The doctors ... not the brand names. Failure to do so would call ...
... Leading pharmaceutical company Lupin Ltd has received tentative approval ... its generic drug Sertraline Hydrochloride for// treatment of major ... will be the AB-rated generic equivalent of Pfizer's Zoloft ... ,"The company intends to launch the generic (drug) ...
... were thought to be far cleaner and healthier as compared ... not true- inner cities are a haven// for unhealthy habits ... smoking and disease rates and dietary habits to understand the ... that towns such as Merthyr Tydfil in Wales happened to ...
... be used for 15 minutes before sleeping to treat insomnia ... based company Helicor, is under clinical trial on 100 patients ... heartbeat by regulated deep breathing, said the online edition of ... several other conditions including anxiety and panic attacks, is said ...
Cached Medicine News:Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... Liquichek ToRCH Plus Control ... used to monitor the performance ... serology instruments and assays. A ... control allow you to monitor ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: